Literature DB >> 11472359

Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females.

T Futatani1, C Watanabe, Y Baba, S Tsukada, H D Ochs.   

Abstract

X-linked agammaglobulinaemia (XLA) is a primary immunodeficiency caused by mutations in the gene coding for Bruton's tyrosine kinase (Btk) and is characterized by an arrest of B-cell development. We analysed Btk protein expression in platelets using flow cytometry and found that normal platelets express large amounts of Btk. Assessment of affected males from 45 unrelated XLA families revealed that platelets of the majority of the patients (37 out of 45 families) had decreased or absent Btk expression, and that platelets from carrier females of these families had both normal and mutated Btk expression, indicating that megakaryocytes in XLA carriers undergo random X-chromosome inactivation. These observations demonstrate that Btk is not crucial for maturation of megakaryocytes and the production of platelets. No correlation between Btk expression in platelets and clinical phenotype was observed in this study. Flow cytometric evaluation using platelets is a simple and rapid method to test Btk expression. It may be used as a screening test for XLA and for carrier detection, followed, if necessary, by more expensive mutation analyses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472359     DOI: 10.1046/j.1365-2141.2001.02905.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  31 in total

1.  A minimally hypomorphic mutation in Btk resulting in reduced B cell numbers but no clinical disease.

Authors:  M E Conley; D M Farmer; A K Dobbs; V Howard; Y Aiba; S A Shurtleff; T Kurosaki
Journal:  Clin Exp Immunol       Date:  2008-01-28       Impact factor: 4.330

Review 2.  How will B-cell-receptor-targeted therapies change future CLL therapy?

Authors:  Jeffrey A Jones; John C Byrd
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

Review 3.  The genetic theory of infectious diseases: a brief history and selected illustrations.

Authors:  Jean-Laurent Casanova; Laurent Abel
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-05-29       Impact factor: 8.929

4.  Types and effects of protein variations.

Authors:  Mauno Vihinen
Journal:  Hum Genet       Date:  2015-01-24       Impact factor: 4.132

Review 5.  Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.

Authors:  J J Shatzel; S R Olson; D L Tao; O J T McCarty; A V Danilov; T G DeLoughery
Journal:  J Thromb Haemost       Date:  2017-03-27       Impact factor: 5.824

Review 6.  Therapeutic strategies for thrombosis: new targets and approaches.

Authors:  Nigel Mackman; Wolfgang Bergmeier; George A Stouffer; Jeffrey I Weitz
Journal:  Nat Rev Drug Discov       Date:  2020-03-04       Impact factor: 84.694

Review 7.  BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Authors:  M Spaargaren; M F M de Rooij; A P Kater; E Eldering
Journal:  Oncogene       Date:  2014-06-23       Impact factor: 9.867

Review 8.  Molecular- and flow cytometry-based diagnosis of primary immunodeficiency disorders.

Authors:  Joao B Oliveira; Thomas A Fleisher
Journal:  Curr Allergy Asthma Rep       Date:  2010-11       Impact factor: 4.806

Review 9.  How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

10.  Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia.

Authors:  Cornelia Brunner; Hans Wolfgang Kreth; Hans D Ochs; Volker Schuster
Journal:  J Clin Immunol       Date:  2002-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.